Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En klinisk studie för att utvärdera Ianalumab hos deltagare med diffus kutan systemisk skleros

6 november 2026 uppdaterad av: Novartis Pharmaceuticals

En randomiserad, dubbelblind, parallell grupp, placebokontrollerad multicenterstudie för att utvärdera effektivitet, säkerhet och tolerabilitet av Ianalumab hos deltagare med diffus kutan systemisk skleros

The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to placebo

Studieöversikt

Status

Aktiv, inte rekryterande

Detaljerad beskrivning

The study consists of the following periods:

  • Screening Period, with a duration of up to 6 weeks;
  • Treatment Period 1, with a duration of 52 weeks;
  • Treatment Period 2 (Open-label treatment), with a duration of 52 weeks;
  • Post-treatment Follow-up Period, with a duration of at least 20 weeks post last dose and up to 2 years.

Studietyp

Interventionell

Inskrivning (Faktisk)

203

Fas

  • Fas 2

Utökad åtkomst

Tillgängligt utanför den kliniska prövningen. Se utökad åtkomstpost.

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Caba, Argentina, C1015ABO
        • Novartis Investigative Site
      • Caba, Argentina, C1427CCL
        • Novartis Investigative Site
      • San Miguel de Tucumán, Argentina, T4000AXL
        • Novartis Investigative Site
    • Buenos Aires
      • CABA, Buenos Aires, Argentina, C1221ADC
        • Novartis Investigative Site
      • Leuven, Belgien, 3000
        • Novartis Investigative Site
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasilien, 40150-150
        • Novartis Investigative Site
    • Paraná
      • Curitiba, Paraná, Brasilien, 80030-110
        • Novartis Investigative Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90035-074
        • Novartis Investigative Site
    • São Paulo
      • Sao Jose Rio Preto, São Paulo, Brasilien, 15090-000
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brasilien, 04038-002
        • Novartis Investigative Site
      • Bogotá, Colombia, 110231
        • Novartis Investigative Site
      • Medellín, Colombia, 050034
        • Novartis Investigative Site
    • Antioquia
      • Medellín, Antioquia, Colombia, 050001
        • Novartis Investigative Site
    • Cundinamarca
      • Bogota, Cundinamarca, Colombia, 110111
        • Novartis Investigative Site
      • Bogota, Cundinamarca, Colombia, 110221
        • Novartis Investigative Site
    • Valle del Cauca Department
      • Cali, Valle del Cauca Department, Colombia, 760012
        • Novartis Investigative Site
      • Le Mans, Frankrike, 72000
        • Novartis Investigative Site
      • Lille, Frankrike, 59037
        • Novartis Investigative Site
      • Paris, Frankrike, 75014
        • Novartis Investigative Site
      • Toulouse, Frankrike, 31054
        • Novartis Investigative Site
    • Arizona
      • Mesa, Arizona, Förenta staterna, 85202
        • Arizona Arthritis and Rheumatology Research PLLC
    • California
      • Los Angeles, California, Förenta staterna, 90095
        • UCLA
      • Newport Beach, California, Förenta staterna, 92663
        • Hoag Hospital
    • Florida
      • Clearwater, Florida, Förenta staterna, 33765
        • Clinical Res Of W Florida
      • Cooper City, Florida, Förenta staterna, 33024
        • GNP Research
      • Plantation, Florida, Förenta staterna, 33324
        • IRIS Research and Development
      • Sarasota, Florida, Förenta staterna, 34239
        • Sarasota Arthritis Res Ctr
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60637
        • University of Chicago Hospitals
    • Michigan
      • Ann Arbor, Michigan, Förenta staterna, 48109
        • Uni Of Michigan Health System
    • New York
      • New York, New York, Förenta staterna, 10021
        • Hospital for Special Surgery
    • Tennessee
      • Jackson, Tennessee, Förenta staterna, 38305
        • West Tennessee Research Institute
    • Texas
      • Bellaire, Texas, Förenta staterna, 77401
        • Novel Research LLC
      • Frisco, Texas, Förenta staterna, 75035
        • Arthritis and Rheumatology Ins
      • Houston, Texas, Förenta staterna, 77054
        • Prolato Clinical Research Center
      • Alexandroupoli, Grekland, 681 00
        • Novartis Investigative Site
      • Athens, Grekland, 115 27
        • Novartis Investigative Site
      • Athens, Grekland, 115 21
        • Novartis Investigative Site
    • Kerala
      • Kochi, Kerala, Indien, 682018
        • Novartis Investigative Site
    • Maharashtra
      • Mumbai, Maharashtra, Indien, 400078
        • Novartis Investigative Site
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, Indien, 110060
        • Novartis Investigative Site
    • New Delhi
      • New Delhi, New Delhi, Indien, 110029
        • Novartis Investigative Site
    • Rajasthan
      • Jaipur, Rajasthan, Indien, 302004
        • Novartis Investigative Site
    • AN
      • Ancona, AN, Italien, 60020
        • Novartis Investigative Site
    • MI
      • Milan, MI, Italien, 20100
        • Novartis Investigative Site
      • Rozzano, MI, Italien, 20089
        • Novartis Investigative Site
    • MO
      • Modena, MO, Italien, 41124
        • Novartis Investigative Site
    • PV
      • Pavia, PV, Italien, 27100
        • Novartis Investigative Site
    • RM
      • Roma, RM, Italien, 00168
        • Novartis Investigative Site
    • VR
      • Verona, VR, Italien, 37134
        • Novartis Investigative Site
      • Hiroshima, Japan, 7348551
        • Novartis Investigative Site
      • Ishikawa, Japan, 9208641
        • Novartis Investigative Site
      • Kyoto, Japan, 6068507
        • Novartis Investigative Site
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 4578510
        • Novartis Investigative Site
      • Toyoake, Aichi-ken, Japan, 4701192
        • Novartis Investigative Site
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 2360004
        • Novartis Investigative Site
    • Saitama
      • Iruma-gun, Saitama, Japan, 3500495
        • Novartis Investigative Site
    • Tokyo
      • Bunkyo-ku, Tokyo, Japan, 1138603
        • Novartis Investigative Site
      • Shinjuku Ku, Tokyo, Japan, 1628666
        • Novartis Investigative Site
    • Toyama
      • Toyama, Toyama, Japan, 9300194
        • Novartis Investigative Site
      • Beijing, Kina, 100191
        • Novartis Investigative Site
      • Tianjin, Kina, 300052
        • Novartis Investigative Site
    • Guangxi
      • Nanning, Guangxi, Kina, 530021
        • Novartis Investigative Site
    • Henan
      • Zhengzhou, Henan, Kina, 450003
        • Novartis Investigative Site
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • Novartis Investigative Site
    • Zhejiang
      • Ningbo, Zhejiang, Kina, 315016
        • Novartis Investigative Site
      • Kuala Lumpur, Malaysia, 59100
        • Novartis Investigative Site
    • Kuala Lumpur
      • Cheras, Kuala Lumpur, Malaysia, 56000
        • Novartis Investigative Site
    • Chihuahua
      • Chihuahua City, Chihuahua, Mexiko, 31000
        • Novartis Investigative Site
    • Jalisco
      • Guadalajara, Jalisco, Mexiko, 44650
        • Novartis Investigative Site
    • Mexico City
      • Mexico City, Mexico City, Mexiko, 11850
        • Novartis Investigative Site
    • Nuevo León
      • Monterrey, Nuevo León, Mexiko, 64460
        • Novartis Investigative Site
      • Bydgoszcz, Polen, 85-168
        • Novartis Investigative Site
      • Warsaw, Polen, 00-874
        • Novartis Investigative Site
      • Vila Nova de Gaia, Portugal, 4434-502
        • Novartis Investigative Site
      • Barcelona, Spanien, 08041
        • Novartis Investigative Site
      • Madrid, Spanien, 28009
        • Novartis Investigative Site
    • Andalusia
      • Málaga, Andalusia, Spanien, 29009
        • Novartis Investigative Site
      • Bristol, Storbritannien, BS10 5NB
        • Novartis Investigative Site
      • London, Storbritannien, NW3 2QG
        • Novartis Investigative Site
      • Seoul, Sydkorea, 04763
        • Novartis Investigative Site
      • Seoul, Sydkorea, 06273
        • Novartis Investigative Site
    • Seoul
      • Seoul, Seoul, Sydkorea, 03080
        • Novartis Investigative Site
      • Changhua, Taiwan, 50006
        • Novartis Investigative Site
      • Kaohsiung City, Taiwan, 833
        • Novartis Investigative Site
      • Taichung, Taiwan, 40447
        • Novartis Investigative Site
      • Taoyuan, Taiwan, 33305
        • Novartis Investigative Site
      • Bangkok, Thailand, 10400
        • Novartis Investigative Site
    • THA
      • Khon Kaen, THA, Thailand, 40002
        • Novartis Investigative Site
    • Fatih
      • Istanbul, Fatih, Turkiet (Türkiye), 34093
        • Novartis Investigative Site
      • Berlin, Tyskland, 13353
        • Novartis Investigative Site
    • Bavaria
      • Würzburg, Bavaria, Tyskland, 97080
        • Novartis Investigative Site
      • Budapest, Ungern, 1083
        • Novartis Investigative Site
    • Baranya
      • Pécs, Baranya, Ungern, 7623
        • Novartis Investigative Site
      • Ho Chi Minh City, Vietnam, 700000
        • Novartis Investigative Site
    • VNM
      • Ho Chi Minh City, VNM, Vietnam, 700000
        • Novartis Investigative Site
      • Graz, Österrike, 8036
        • Novartis Investigative Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 70 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Key Inclusion Criteria:

  • Male and female participants >= 18 and =< 70 years (at the time of the screening visit).

  • Diagnosis of systemic sclerosis, as defined by the 2013 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) classification criteria for SSc (van den Hoogen et al 2013) and meet the dcSSc subset classification according to LeRoy (LeRoy 1988)

  • Disease duration of =< 60 months (defined as time from the first non-Raynaud phenomenon manifestation, e.g., puffy hands, scleroderma, digital ulcers, arthralgia, dyspnea)

  • mRSS units of >= 15 and =< 45 at the time of the screening visit

  • Active disease that meets at least one of the following criteria at screening:

    • Disease duration of =< 18 months defined as time from the first non-Raynaud phenomenon manifestation
    • Increase in mRSS of >= 3 units compared with the most recent assessment performed within the previous 6 months
    • Involvement of one new body area and an increase in mRSS of >= 2 units compared with the most recent assessment performed within the previous 6 months
    • Involvement of two new body areas within the previous 6 months
    • Elevated acute phase reactants (ESR) >= 30 mm/hr or high-sensitivity C-reactive protein (hsCRP) >= 6 mg/L)
    • Presence of SSc-interstitial lung disease (ILD) and ATA autoantibody positivity
    • Modified EUSTAR disease activity index (mDAI) ≥ 2.5
  • Participant must be positive for at least one of the following autoantibodies:

    • anti-topoisomerase I (ATA) (also known as anti-SCL-70)
    • anti-RNA polymerase III (anti-RNAP3)
    • anti-nuclear antibody (ANA) (≥ 1:80) Participants who are positive only for ANA (while being negative for both ATA /anti-RNAP3) will be limited to 30% of the overall randomized study population.

Key Exclusion Criteria:

  • Rheumatic disease other than dcSSc, including limited cutaneous disease (lcSSc) or sine scleroderma at the screening visit. Secondary Sjogren's disease and scleroderma myopathy are not exclusionary.
  • Positive anti-centromere antibody (ACA+) without positive ATA or anti-RNAP3 autoantibody result at the screening visit
  • Previous improvement (decrease) in mRSS > 10 units
  • Pulmonary disease with FVC ≤ 50% of predicted or diffusing capacity of the lung for carbon monoxide (DLCO, corrected for hemoglobin) ≤ 40% of predicted at the screening visit
  • WHO Functional Class 3 or higher assessment for pulmonary arterial hypertension (PAH, as defined on right heart catheterization), receiving IV therapy for PAH or evidence of other moderately severe pulmonary disease
  • Participants treated with cyclophosphamide within 12 weeks prior to Baseline.
  • Prior use of a B-cell depleting therapy other than ianalumab (e.g., rituximab, other anti-CD20 mAb, anti-CD22 mAb, or anti-CD52 mAb) administered within 36 weeks prior to randomization, or as long as B cell count is less than the lower limit of normal or baseline value prior to receipt of B cell-depleting therapy (whichever is lower).
  • Treatment with biologic agents, such as intravenous immunoglobulin or monoclonal antibodies, including marketed drugs, within 12 weeks or 5 half-lives (whichever is longer) prior to baseline visit, unless explicitly allowed in inclusion criteria.
  • Treatment with any investigational agent within ≤ 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of the baseline visit.
  • Use of anti-fibrotic agents including colchicine, D-penicillamine, pirfenidone, or tyrosine kinase inhibitors (e.g., nintedanib, nilotinib, imatinib, dasatinib) in the 4 weeks prior to baseline visit. Patients with SSc-ILD requiring antifibrotics for management of ILD during the study, as per investigator judgement, should be excluded.
  • Previous treatment with chlorambucil, bone marrow transplantation or total lymphoid irradiation.
  • Women of childbearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they are using highly effective methods of contraception (failure rate < 1% per year) while taking study treatment and for 6 months after stopping study treatment.

Other protocol-defined inclusion/exclusion criteria may apply.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: VAY736 (Ianalumab)

Treatment Period 1:

Ianalumab subcutaneous (s.c.) injection as defined in the protocol

Treatment Period 2:

Open-label (OL) Ianalumab subcutaneous (s.c.) injection as defined in the protocol

subcutaneous (s.c.) injection as defined in the protocol

Andra namn:
  • VAY736
Placebo-jämförare: Placebo

Treatment Period 1:

Placebo to Ianalumab subcutaneous (s.c.) injection as defined in the protocol

Treatment Period 2:

Open-label (OL) Ianalumab subcutaneous (s.c.) injection as defined in the protocol

subcutaneous (s.c.) injection as defined in the protocol

Andra namn:
  • VAY736

Ianalumab matching placebo subcutaneous (s.c.) injection as defined in the protocol

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
3/5 rCRISS25 response
Tidsram: Week 52

To demonstrate the superiority of ianalumab, compared to placebo, in achieving 3/5 Revised Composite Response Index in Systemic Sclerosis 25 (rCRISS25) response at Week 52

Week 52

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change from baseline in FVC% predicted at Week 52
Tidsram: Week 52

To demonstrate the superiority of ianalumab, compared to placebo, on change from baseline in percent-predicted forced vital capacity (FVC%) at Week 52

Week 52
Change from baseline in mRSS at Week 52
Tidsram: Week 52

To demonstrate the superiority of ianalumab, compared to placebo, on change from baseline in modified Rodnan Skin Score (mRSS) at Week 52

Week 52
Change from baseline in HAQ-DI at Week 52
Tidsram: Week 52

To demonstrate the superiority of ianalumab, compared to placebo, on change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 52

Week 52
Ianalumab concentrations in serum during treatment and Follow-up Period
Tidsram: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, Week 64, Week 76, Week 88, Week 104, Week 108, Week 112, Week 116, Week 120, Week 124 and Week 208

To assess the pharmacokinetics of ianalumab

Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, Week 64, Week 76, Week 88, Week 104, Week 108, Week 112, Week 116, Week 120, Week 124 and Week 208
Incidence and titer of anti-drug (ianalumab) antibodies (ADAs) in serum over time
Tidsram: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, Week 64, Week 76, Week 88, Week 104, Week 124, Week 208

To evaluate the immunogenicity of ianalumab

Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, Week 64, Week 76, Week 88, Week 104, Week 124, Week 208
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: Up to Week 208

The distribution of adverse events for ianalumab will be done via the analysis of frequencies for Adverse Event (AEs) and Serious Adverse Event (SAEs) through the monitoring of relevant clinical and laboratory safety parameters.

Up to Week 208

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

9 oktober 2024

Primärt slutförande (Beräknad)

30 juli 2027

Avslutad studie (Beräknad)

31 juli 2034

Studieregistreringsdatum

Först inskickad

17 juni 2024

Först inskickad som uppfyllde QC-kriterierna

17 juni 2024

Första postat (Faktisk)

24 juni 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

9 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera